Results 21 to 30 of about 9,231 (199)

Murine Models of Myelofibrosis [PDF]

Cancers, 2020
Myelofibrosis (MF) is subtype of myeloproliferative neoplasm (MPN) characterized by a relatively poor prognosis in patients. Understanding the factors that drive MF pathogenesis is crucial to identifying novel therapeutic approaches with the potential to improve patient care.
Sebastien Jacquelin, Frederike Kramer, Ann Mullally, Steven W. Lane   +3 more
openaire   +5 more sources

Myelofibrosis with myeloid metaplasia (MMM) - Idiopathic myelofibrosis - Agnogenic myeloid metaplasia [PDF]

, 2007
Review on Myelofibrosis with myeloid metaplasia (MMM) - Idiopathic myelofibrosis - Agnogenic myeloid metaplasia, with data on clinics, and the genes ...
Cavazzini, F, CUNEO, Antonio, Cuneo, A, CAVAZZINI, Francesco   +3 more
core   +1 more source

Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation

Haematologica, 2016
Myelofibrosis is a myeloproliferative neoplasm that results in cytopenia, bone marrow fibrosis and extramedullary hematopoiesis. Allogeneic hematopoietic stem cell transplantation is the only curative treatment but is associated with a risk of delayed ...
Christina Hart, Sabine Klatt, Johann Barop, Gunnar Müller, Roland Schelker, Ernst Holler, Elisabeth Huber, Wolfgang Herr, Jochen Grassinger   +8 more
doaj   +1 more source

Fedratinib in myelofibrosis

Blood Advances, 2020
Abstract Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in 2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to yield low-nanomolar activity against JAK2 (50% inhibitory concentration = 3 nM) and was identified to be selective for JAK2 relative to other JAK family ...
Ann Mullally, John Hood, Claire Harrison, Ruben Mesa   +3 more
openaire   +2 more sources

PATHOMORPHOLOGICAL ANALYSIS OF TREPANOBIOPTATES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOCYTIC LEUKEMIA: ASSESSMENT OF THE PROGNOSTIC VALUE OF MYELOFIBROSIS WHEN COMPARED WITH CLINICAL DATA

Сибирский научный медицинский журнал, 2019
The aim of the study was to study the relationship between the qualitative and quantitative characteristics of myelofibrosis and the clinical manifestations of chronic myeloid leukemia and chronic lymphocytic leukemia. Material and methods.
T. Y. Dolgikh, E. V. Vinogradova, V. I. Kapustina, S. R. Senchukova   +3 more
doaj   +1 more source

Primary Myelofibrosis with Mesenteric Extramedullary Haematopoiesis [PDF]

Journal of Clinical and Diagnostic Research, 2018
Primary myelofibrosis or chronic idiopathic myelofibrosis is a myeloproliferative neoplasm characterized by proliferation of abnormal haematopoietic stem cells in bone marrow resulting in replacement of marrow with fibrotic scar tissue.
Saurabh Kumar, Shaloo Shaloo, Juhi Chawla, Subha Ashok, Shalini Thapar Laroia   +4 more
doaj   +1 more source

Case Report: Effects of Secondary Hyperparathyroidism Treatment on Improvement of Juvenile Nephronophthisis-Induced Pancytopenia and Myelofibrosis

Frontiers in Pediatrics, 2021
Secondary hyperparathyroidism (HPT) is a common complication of end-stage renal disease (ESRD) and may be an important precipitating factor for the development of myelofibrosis.
Keishiro Amano, Hidemi Toyoda, Kouhei Nishikawa, Tomohiro Murata, Masahiro Hirayama   +4 more
doaj   +1 more source

Disseminated tuberculosis with myelofibrosis presentation: a case report

Journal of Medical Case Reports, 2021
Background Primary myelofibrosis is a rare myeloproliferative disorder in middle-aged and old adults and should be distinguished from secondary and reactive causes of bone marrow fibrosis because, in reactive fibrosis, treatment approaches depend on the ...
Mahdi Khatuni, Marziyeh Ghalamkari, Fereshteh Ameli, Habibeh Yekehtaz   +3 more
doaj   +1 more source

Thalidomide treatment in a myelofibrosis patient with leukemia transformation

, 2017
Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis.
Huang, Wei-Han;Li, Ming-Shing;Chu, Sung-Chao;Wang, Tso-Fu;Kao, Ruey-Ho;Wu, Yi-Feng
core   +1 more source

The human myeloproliferative disorders: molecular pathogenesis and clonal heterogeneity [PDF]

, 2010
The classical myeloproliferative disorders (MPD), comprising essential thrombocythaemia (ET), polycythaemia vera (PV) and idiopathic myelofibrosis (IMF), are clonal premalignant haematopoietic neoplasms associated with activating mutations in signalling ...

core   +2 more sources